Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

farmaco sa, im - bendazolum - solutie injectabila - 1%

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidină - leucemie, mieloidă, acută - agenți antineoplazici - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Uniunea Europeană - română - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agenți antineoplazici - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq cum este indicat în monoterapie pentru tratamentul pacienților adulți cu nsclc local avansat sau metastatic după chimioterapie anterioară. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq cum este indicat în monoterapie pentru tratamentul pacienților adulți cu nsclc local avansat sau metastatic după chimioterapie anterioară. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Uniunea Europeană - română - EMA (European Medicines Agency)

pfizer europe ma eeig - tafamidis - amiloidoza - alte medicamente pentru sistemul nervos - vyndaqel este indicat pentru tratamentul de amiloidoză transthyretin la pacienţii adulţi cu polineuropatie simptomatic etapa 1 pentru a întârzia tulburări neurologice periferice.

Uniunea Europeană - română - EMA (European Medicines Agency)

orphelia pharma sas - vigabatrin - spasms, infantile; epilepsies, partial - antiepileptice, - kigabeq este indicat la sugari și copiii de la 1 lună până la mai puțin de 7 ani pentru:tratamentul în monoterapie de spasme infantile (sindromul lui). tratamentul în asociere cu alte medicamente antiepileptice pentru pacientii cu rezistente epilepsie parțială (focale, crize convulsive), cu sau fără generalizare secundară, care este în cazul în care toate celelalte adecvate de medicament combinațiile s-au dovedit inadecvate sau nu au fost tolerate.

Uniunea Europeană - română - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Uniunea Europeană - română - EMA (European Medicines Agency)

merz pharmaceuticals gmbh - memantină clorhidrat - boala alzheimer - alte medicamente anti-demență - tratamentul pacienților cu boală alzheimer moderată până la severă.

Uniunea Europeană - română - EMA (European Medicines Agency)

mylan pharmaceuticals limited - memantină clorhidrat - boala alzheimer - other anti-dementia drugs, psychoanaleptics, - tratamentul pacienților cu boală alzheimer moderată până la severă.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

baxter s.a. - belgia - desfluranum - lichid pt. vapori de inhal. - 100% - anestezice generale derivati halogenati ai hidrocarburilor

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

kusum healthcare pvt.ltd - memantinum - comprimate filmate - 5 mg